IRIS
SIGNORIELLO, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 988
NA - Nord America 813
AS - Asia 153
OC - Oceania 4
AF - Africa 1
Totale 1.959
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 808
IE - Irlanda 436
IT - Italia 162
GB - Regno Unito 136
DE - Germania 97
SG - Singapore 68
CN - Cina 60
UA - Ucraina 39
GR - Grecia 31
FR - Francia 28
FI - Finlandia 16
SE - Svezia 13
KR - Corea 12
BE - Belgio 9
HU - Ungheria 6
TR - Turchia 6
IN - India 5
PL - Polonia 5
CA - Canada 4
CZ - Repubblica Ceca 4
NL - Olanda 3
AU - Australia 2
IL - Israele 2
NZ - Nuova Zelanda 2
DK - Danimarca 1
EG - Egitto 1
ES - Italia 1
MX - Messico 1
RU - Federazione Russa 1
Totale 1.959
Salva come PNG Salva come JPEG
Città #
Dublin 434
Chandler 156
Jacksonville 78
Princeton 56
Roxbury 56
Bremen 48
Singapore 42
Caserta 41
Cambridge 33
New York 33
Ann Arbor 32
Medford 30
Redhill 26
Beijing 22
Boardman 22
Munich 17
Wilmington 16
Des Moines 15
Naples 15
Norwalk 12
Seoul 12
Milan 11
Brussels 9
Helsinki 8
Nanjing 7
Rome 7
Redwood City 6
San Mateo 6
Woodbridge 6
Cercola 5
Houston 5
Mountain View 5
Wroclaw 5
Ashburn 4
Brno 4
Marcianise 4
Nanchang 4
San Giorgio A Cremano 4
Darmstadt 3
Fairfield 3
Hyderabad 3
Jinan 3
Lappeenranta 3
Los Angeles 3
Napoli 3
Farmington 2
Guangzhou 2
Philadelphia 2
Piemonte 2
Shenyang 2
Tianjin 2
Wuhan 2
Zhengzhou 2
Acibadem 1
Ancona 1
Andover 1
Atlanta 1
Auburn Hills 1
Benevento 1
Boydton 1
Casoria 1
Catania 1
Changchun 1
Chicago 1
Duncan 1
Elk Grove Village 1
Fremantle 1
Gallatin 1
Groningen 1
Haikou 1
Hangzhou 1
Kunming 1
Ladispoli 1
Letchworth 1
Limbiate 1
Lviv 1
Marlborough 1
Mexico City 1
Modica 1
Montréal 1
Moscow 1
Oakleigh South 1
Ottawa 1
Pamplona 1
Pavia 1
Piacenza 1
Pune 1
Putignano 1
Reston 1
Rockville 1
Sacramento 1
Sala Consilina 1
Salerno 1
San Bruno 1
Seattle 1
Shanghai 1
Soehrewald 1
Southend 1
Tel Aviv 1
Toronto 1
Totale 1.380
Salva come PNG Salva come JPEG
Nome #
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 90
Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis 64
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 59
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 56
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome 54
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 53
Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families 53
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis 51
12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate 47
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 46
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study 45
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 44
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study. 44
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 41
Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 41
Diagnostic contribution of magnetic resonance imaging in an atypical presentation of motor neuron disease 40
Migraine as possible red flag of PFO presence in suspected demyelinating disease 39
Systematic Review on the Role of Lobar Cerebral Microbleeds in Cognition 39
Is the pathology of posterior cortical atrophy clinically predictable? 37
Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis 37
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 37
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 37
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 36
Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study 36
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 35
Disability assessment using Google Maps 34
Cd19 cell count at baseline predicts b cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab 34
Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study 33
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity 33
Integrated cognitive and neuromotor rehabilitation in multiple sclerosis: A pragmatic study 32
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 31
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab 31
Preliminary results of the FASM study, an on-going italian active pharmacovigilance project 31
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 30
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 29
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 29
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study 29
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 28
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 28
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 27
Correction to: Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 27
Clinical activity after fingolimod cessation: disease reactivation or rebound? 27
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 25
Apparently isolated CNS involvement in Erdheim-Chester disease: Case report 24
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery. 24
A real-world study of alemtuzumab in a cohort of Italian patients 24
Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series 23
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis 21
Ocrelizumab in a case of refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with antibodies anti Rituximab 21
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 20
A real-world study of alemtuzumab in a cohort of Italian patients 20
Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis 19
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 19
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 19
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 19
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 17
Therapeutic Plasmapheresis: a revision of literature 16
Nociplastic Pain in Multiple Sclerosis Spasticity: Dermatomal Evaluation, Treatment with Intradermal Saline Injection and Outcomes Assessed by 3D Gait Analysis: Review and a Case Report 16
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 15
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study 14
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 14
Italian Alemtuzumab Study Group. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. 14
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence 13
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study 13
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis 11
Whole-brain propagation delays in multiple sclerosis, a combined tractography - magnetoencephalography study 10
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 8
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis 7
null 7
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 5
Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) 5
Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients' Blood 5
Adiponectin Alleviates Cell Injury due to Cerebrospinal Fluid from Multiple Sclerosis Patients by Inhibiting Oxidative Stress and Proinflammatory Response 4
Totale 2.146
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.185
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.185
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020143 0 27 4 3 25 9 27 7 4 13 18 6
2020/2021193 29 2 7 9 24 1 34 13 9 21 33 11
2021/2022451 13 42 7 14 103 8 10 10 30 51 29 134
2022/2023750 76 18 11 48 82 45 1 38 382 7 23 19
2023/2024415 26 11 24 24 113 43 33 5 18 4 26 88
2024/202529 3 26 0 0 0 0 0 0 0 0 0 0
Totale 2.146